Real-World Studies
Nonlinear TET2 Variant Allele Frequency Refines CMML Prognostic Models
Wang et alBlood neoplasia

In 1,206 patients with chronic myelomonocytic leukemia (CMML) from a UK discovery cohort and two validation cohorts (validation cohort 1, an international cohort; validation cohort 2, a French cohort with CD14+ monocyte sequencing), segmented regression of TET2 variant allele frequency (VAF) distributions identified two reproducible inflection points (discovery cohort: 32% and 55%; validation cohort 1: 33% and 54%; validation cohort 2: 36% and 56%), indicating a consistent subdivision of TET2 mutation burden. Restricted cubic spline Cox regression showed a nonlinear relationship between TET2 VAF and survival, where clinical risk was lowest near a VAF of 39% (the empirical first quartile), while patients with TET2 wild-type status experienced hazards comparable to individuals with high VAF.
Applying a continuous per-integer TET2 VAF adjustment to existing risk systems—including the CMML-specific Prognostic Scoring System-Molecular (CPSS-Mol), Groupe Français des Myélodysplasies (GFM) model, and Mayo Molecular Model—improved discrimination and group-level stratification for overall survival and acute myeloid leukemia-free survival. The adjusted scores achieved Harrell C-index gains in 16 of 18 comparisons and significant integrated discrimination improvement in all 18 comparisons (P < .01), suggesting that TET2 VAF functions as a continuous prognostic variable that can refine standard CMML risk models.
Key Takeaways
- Restricted cubic spline Cox regression revealed a nonlinear relationship between TET2 variant allele frequency (VAF) and survival, with mortality risk lowest near a VAF of 39% and TET2 wild-type patients exhibiting hazards comparable to those with high VAF.
- Incorporating per-integer TET2 VAF adjustments into CPSS-Mol, GFM, and Mayo Molecular Model scores improved discrimination for overall survival and acute myeloid leukemia-free survival, yielding Harrell C-index gains in 16 of 18 comparisons and significant integrated discrimination improvement across all 18 comparisons (P < .01).
Read the original sourceBlood neoplasia
